JP2002500181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002500181A5 JP2002500181A5 JP2000527236A JP2000527236A JP2002500181A5 JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5 JP 2000527236 A JP2000527236 A JP 2000527236A JP 2000527236 A JP2000527236 A JP 2000527236A JP 2002500181 A5 JP2002500181 A5 JP 2002500181A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- riluzole
- per day
- composition according
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 9
- 229960004181 riluzole Drugs 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 229940107161 Cholesterol Drugs 0.000 description 2
- 208000001187 Dyskinesias Diseases 0.000 description 2
- 206010043118 Tardive dyskinesia Diseases 0.000 description 2
- 230000000561 anti-psychotic Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL122883 | 1998-01-09 | ||
| IL12288398A IL122883A0 (en) | 1998-01-09 | 1998-01-09 | Pharmaceutical compositions for the treatment of dyskinesias |
| IL127102 | 1998-11-17 | ||
| IL12710298A IL127102A0 (en) | 1998-11-17 | 1998-11-17 | Pharmaceutical compositions for the treatment of dyskinesias |
| PCT/IL1999/000003 WO1999034785A2 (en) | 1998-01-09 | 1999-01-05 | Treatment of dyskinesias |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002500181A JP2002500181A (ja) | 2002-01-08 |
| JP2002500181A5 true JP2002500181A5 (pt) | 2006-03-02 |
Family
ID=26323572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000527236A Pending JP2002500181A (ja) | 1998-01-09 | 1999-01-05 | ジスキネジーの処置 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1043996A2 (pt) |
| JP (1) | JP2002500181A (pt) |
| KR (1) | KR20010033978A (pt) |
| CN (1) | CN1290166A (pt) |
| AU (1) | AU1780699A (pt) |
| BR (1) | BR9906821A (pt) |
| CA (1) | CA2317811A1 (pt) |
| NO (1) | NO20003529L (pt) |
| PL (1) | PL342098A1 (pt) |
| WO (1) | WO1999034785A2 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002539162A (ja) * | 1999-03-12 | 2002-11-19 | アベンテイス・フアルマ・ソシエテ・アノニム | リルゾールおよびａｍｐａ受容体アンタゴニストの組み合わせ剤を用いる筋萎縮性側索硬化症の治療 |
| FR2790670A1 (fr) * | 1999-03-12 | 2000-09-15 | Aventis Pharma Sa | Association riluzole et antagoniste des recepteurs ampa |
| FR2801793B1 (fr) * | 1999-12-01 | 2003-07-04 | Aventis Pharma Sa | Association d'une ergoline et de riluzole et son utilisation comme medicament |
| US6297254B1 (en) | 1999-12-01 | 2001-10-02 | Aventis Pharma S. A. | Method for the prevention or treatment of a motoneuron disease |
| FR2809620B1 (fr) * | 2000-06-05 | 2002-08-02 | Aventis Pharma Sa | Utilisation du riluzole ou ses sels pour la prevention et le traitement de l'adrenoleucodystrophie |
| ES2203563T3 (es) * | 2001-05-08 | 2004-04-16 | Schwarz Pharma Ag | Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| FR2700117B1 (fr) * | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
-
1999
- 1999-01-05 BR BR9906821-4A patent/BR9906821A/pt not_active IP Right Cessation
- 1999-01-05 PL PL99342098A patent/PL342098A1/xx unknown
- 1999-01-05 AU AU17806/99A patent/AU1780699A/en not_active Abandoned
- 1999-01-05 WO PCT/IL1999/000003 patent/WO1999034785A2/en not_active Application Discontinuation
- 1999-01-05 JP JP2000527236A patent/JP2002500181A/ja active Pending
- 1999-01-05 KR KR1020007007567A patent/KR20010033978A/ko not_active Application Discontinuation
- 1999-01-05 CN CN99802790A patent/CN1290166A/zh active Pending
- 1999-01-05 CA CA002317811A patent/CA2317811A1/en not_active Abandoned
- 1999-01-05 EP EP99900116A patent/EP1043996A2/en not_active Withdrawn
-
2000
- 2000-07-07 NO NO20003529A patent/NO20003529L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004056337A3 (en) | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats | |
| YU37301A (sh) | Farmaceutski preparat za modifikovano oslobađanje sensitizera insulina i drugog antidijabetskog agensa | |
| JO2555B1 (en) | Forms of oral doses of propiferine or pharmaceutically acceptable salts thereof with an extended release of active agent | |
| WO2001019337A3 (en) | Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing | |
| AU2277101A (en) | Stable extended release oral dosage composition | |
| AU2001283563A1 (en) | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent | |
| AU7375598A (en) | Stable oral pharmaceutical dosage forms | |
| HK1050839A1 (en) | Use of pharmaceutical compositions comprising oxcarbazepine in the fasted state | |
| SG127714A1 (en) | Method of treating metabolic disorders, especiallydiabetes, or a disease or condition associated wi th diabetes | |
| JP2002511411A5 (pt) | ||
| PL348734A1 (en) | New sustained release oral formulations | |
| YU14502A (sh) | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva | |
| AU1724301A (en) | Hydrogel-driven layered drug dosage form | |
| AU9018898A (en) | Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments | |
| GEP20063882B (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| HK1045113A1 (zh) | 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式 | |
| AU2003238221A1 (en) | Ibuprofen suspension | |
| CA2325739A1 (en) | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator | |
| ZA200308221B (en) | Pharmaceutical compositions for oral and topical administration. | |
| BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
| JP2002522501A5 (pt) | ||
| AR049196A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
| CA2350659A1 (en) | Pharmaceutical composition for modified release insulin sensitiser | |
| JP2002500181A5 (pt) | ||
| JP2001513504A5 (pt) |